By contrast, HCMV(+) controls and MS patients showed increased proportions of PLZF(–) cells not only in CD56dim NK cells but, remarkably, also among the CD56bright subset (Figure 2C); these PLZF(–) NK cells were confirmed to display the characteristic CD56bright NKG2A(+) CD16(–) phenotype (Supplementary Figure 1). This evidence concerns the gene FCGR3A and myeloid sarcoma.